Key Highlights
- Boston Scientific slipped on Friday, with no company-specific news found, as health care was the only one of the S&P 500's 11 sectors to fall.
- Drug distributors Cardinal Health, McKesson and Cencora fell alongside life sciences software firm Veeva Systems and biotech Alnylam, with Intuitive Surgical and DexCom also among the Nasdaq-100's laggards.
- Health care was actually a relative bright spot in the September jobs data, adding 17,000 positions with ambulatory care contributing 13,000 and hospitals 12,000, though investors were focused elsewhere.
- The broader market rallied on a weak jobs report that cut odds of another Federal Reserve hike, with Tesla leading consumer discretionary to the top of the sector table while MedTech did not attract the same flow of money.
Boston Scientific (NYSE:BSX) slipped on Friday, ending among the S&P 500's weaker stocks on a day when health care was the only sector in the index to fall. The Massachusetts-based company makes medical devices used in minimally invasive procedures, including heart rhythm treatments, stents, devices for structural heart repair and tools for urology and endoscopy. It has been one of the larger growth stories in medical technology in recent years. No company-specific news on Boston Scientific was found for the session.
Health Care Stood Apart
Friday was a strong day for the market overall. The S&P 500 climbed 56.27 points to 7,722.72, the Dow Jones Industrial Average gained 250.40 points and the Nasdaq-100 hit a record close of 30,807.93. Ten of the 11 S&P 500 sectors rose.
Health care was the only exception, slipping by a whisker. Boston Scientific had company in the red: drug distributors Cardinal Health, McKesson and Cencora fell, as did life sciences software provider Veeva Systems and biotech Alnylam. Surgical robot maker Intuitive Surgical and diabetes device maker DexCom were also among the Nasdaq-100's laggards.
The sector's weakness carried over from Thursday, when health care lagged the market and life sciences tools makers such as Danaher and Thermo Fisher came under pressure.
A Jobs Report That Favoured Growth
The day's market mood was shaped by the September jobs report. The economy added just 29,000 jobs, far short of the roughly 84,000 economists expected. Downward revisions to July and August removed a combined 60,000 jobs, and the Unemployment rate ticked up.
The soft data cut expectations for another Federal Reserve rate hike. The Fed, led by Chair Kevin Warsh, raised rates on September 16 for the first time since 2023, responding to Inflation that re-accelerated with the oil shock from the war with Iran. After the report, odds of another hike at the October 27-28 meeting fell to roughly one in five from roughly two in three earlier in the week.
Investors responded by buying growth and AI stocks, particularly semiconductors. Tesla led consumer discretionary to the top of the sector table. Medtech, which has typically been viewed as a steady, defensive growth area, did not attract the same flow of money.
Steady Demand, Shifting Appetite
Interestingly, health care was one of the stronger areas of the jobs report. The sector added 17,000 positions, with ambulatory care adding 13,000 and hospitals 12,000. Busy hospitals and clinics are generally a healthy sign for procedure volumes, which drive Demand for Boston Scientific's products.
But on Friday, investors were less focused on fundamentals than on interest rates and AI momentum. Treasury yields fell after the jobs report and then reversed to close higher, with the 10-year near its highest level since 2002.
Watching for a Health Care Rebound
The next major event for the broad market is the Fed's October 27-28 meeting. A lower chance of further hikes could support growth-oriented stocks across sectors, including medtech.
Earnings season opens with PepsiCo on October 8 and Delta on October 9, with the big banks on October 13 and 14. Analysts expect strong double-digit Earnings growth for the S&P 500 in the third quarter, with estimates raised during the quarter rather than cut.
For Boston Scientific, investors will be watching whether health care can recover from two soft sessions, and whether the rotation into chips and AI hardware continues to leave medical device stocks on the sidelines.






Please wait processing your request...